Ertugliflozin: Difference between revisions
Created page with "Category: DrugsCategory: Sodium-glucose co-transporter 2 (SGLT2) inhibitor '''Antidiabetic Drug''' '''Drug class: :Category: Sod..." |
No edit summary |
||
| Line 6: | Line 6: | ||
'''Ertugliflozin (STEGLATRO)'''（中文：[[埃格列淨]]） | '''Ertugliflozin (STEGLATRO)'''（中文：[[埃格列淨]]） | ||
==Common Strengths of Ertugliflozin Tablet== | |||
Ertugliflozin tablets are available in the following strengths: | |||
*5 mg and 15 mg tablets | |||
==Drug Trade Names of Ertugliflozin Tablet== | |||
Steglatro | |||
It is also sold under various brand names when combined with other antidiabetic medications, such as: | |||
*STEGLUJAN TABLET 5MG/100MG: Ergugliflozin 5mg + Sitagliptin 100mg | |||
==Drug Usage== | |||
Treatment of type 2 diabetes mellitus | |||
==Mechanism of Action== | |||
Inhibits sodium-glucose co-transporter 2 (SGLT2) in the proximal renal tubules, reducing glucose reabsorption and increasing urinary glucose excretion | |||
==Route of Administration== | |||
Oral | |||
==Dosages== | |||
*Type 2 diabetes: Starting dose 5 mg once daily, can be increased to 15 mg once daily | |||
*Not specifically indicated for hypertension, heart failure, or diabetic kidney disease | |||
Renal dose based on eGFR: | |||
*eGFR ≥60 mL/min/1.73 m<sup>2</sup>: No dose adjustment required | |||
*eGFR 30 to <60 mL/min/1.73 m<sup>2</sup>: Not recommended to initiate therapy | |||
*eGFR <30 mL/min/1.73 m<sup>2</sup>: Contraindicated | |||
==Side Effects== | |||
{| class="wikitable" | |||
!style="text-align: left"| Frequency | |||
!Adverse reactions | |||
|- | |||
| rowspan="3" | '''Common | |||
| Urinary tract infections | |||
|- | |||
| Male and female genital mycotic infections | |||
|- | |||
| Increased urination | |||
|- | |||
| rowspan="2" | '''Uncommon | |||
| Volume depletion | |||
|- | |||
| Diabetic ketoacidosis (DKA) - a condition where blood becomes too acidic | |||
|} | |||
==Pharmacokinetics== | |||
*Absorption | |||
**Rapidly absorbed, peak plasma concentrations within 1 hour | |||
*Metabolism | |||
**Primary metabolism via UGT1A9 and UGT2B7-mediated O-glucuronidation | |||
*Elimination | |||
**Half-life approximately 17 hours | |||
*Drug duration of action | |||
**24 hours | |||
==Drug Precautions== | |||
'''Pregnancy | |||
Not recommended | |||
'''Breastfeeding | |||
Not recommended | |||
'''Children and Elderly | |||
Not recommended for children under 18 years. No dose adjustment is required for elderly patients | |||
'''Renal Impairment | |||
Use with caution, dosage adjustments based on eGFR | |||
'''Monitoring Requirements | |||
Renal function, volume status, signs of ketoacidosis | |||
'''Drug Interaction | |||
May increase the risk of hypoglycemia when used with insulin or insulin secretagogues | |||
==FAQ== | |||
'''How Should I Take the Tablet? | |||
Take once daily in the morning, with or without food | |||
'''What Should I Avoid While Taking? | |||
Avoid excessive alcohol consumption and dehydration | |||
'''What Happens if I Miss a Dose? | |||
Take it as soon as you remember. If it is close to your next dose, skip the missed dose and continue with your regular schedule. Do not take a double dose. | |||
Latest revision as of 04:39, 5 July 2024
Drug class: Sodium-glucose co-transporter 2 (SGLT2) inhibitor
Ertugliflozin (STEGLATRO)（中文：埃格列淨）
Common Strengths of Ertugliflozin Tablet[edit]
Ertugliflozin tablets are available in the following strengths:
- 5 mg and 15 mg tablets
Drug Trade Names of Ertugliflozin Tablet[edit]
Steglatro
It is also sold under various brand names when combined with other antidiabetic medications, such as:
- STEGLUJAN TABLET 5MG/100MG: Ergugliflozin 5mg + Sitagliptin 100mg
Drug Usage[edit]
Treatment of type 2 diabetes mellitus
Mechanism of Action[edit]
Inhibits sodium-glucose co-transporter 2 (SGLT2) in the proximal renal tubules, reducing glucose reabsorption and increasing urinary glucose excretion
Route of Administration[edit]
Oral
Dosages[edit]
- Type 2 diabetes: Starting dose 5 mg once daily, can be increased to 15 mg once daily
- Not specifically indicated for hypertension, heart failure, or diabetic kidney disease
Renal dose based on eGFR:
- eGFR ≥60 mL/min/1.73 m2: No dose adjustment required
- eGFR 30 to <60 mL/min/1.73 m2: Not recommended to initiate therapy
- eGFR <30 mL/min/1.73 m2: Contraindicated
Side Effects[edit]
| Frequency | Adverse reactions |
|---|---|
| Common | Urinary tract infections |
| Male and female genital mycotic infections | |
| Increased urination | |
| Uncommon | Volume depletion |
| Diabetic ketoacidosis (DKA) - a condition where blood becomes too acidic |
Pharmacokinetics[edit]
- Absorption
- Rapidly absorbed, peak plasma concentrations within 1 hour
- Metabolism
- Primary metabolism via UGT1A9 and UGT2B7-mediated O-glucuronidation
- Elimination
- Half-life approximately 17 hours
- Drug duration of action
- 24 hours
Drug Precautions[edit]
Pregnancy
Not recommended
Breastfeeding
Not recommended
Children and Elderly
Not recommended for children under 18 years. No dose adjustment is required for elderly patients
Renal Impairment
Use with caution, dosage adjustments based on eGFR
Monitoring Requirements
Renal function, volume status, signs of ketoacidosis
Drug Interaction
May increase the risk of hypoglycemia when used with insulin or insulin secretagogues
FAQ[edit]
How Should I Take the Tablet?
Take once daily in the morning, with or without food
What Should I Avoid While Taking?
Avoid excessive alcohol consumption and dehydration
What Happens if I Miss a Dose?
Take it as soon as you remember. If it is close to your next dose, skip the missed dose and continue with your regular schedule. Do not take a double dose.
